In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
- TRADE NAME: Tasigna (Novartis)
- INDICATIONS: Chronic myelogenous leukemia
- CLASS: Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor), Bcr-Abl tyrosine kinase inhibitor / (Breakpoint cluster region Abelson (Bcr-Abl) tyrosine kinase inhibitor, Tyrosine kinase inhibitor, Vascular endothelial growth factor (VEGF) inhibitor / antagonist
- HALF-LIFE: 17 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Amiodarone, Amitriptyline, Amoxapine, Arsenic, Astemizole, Bepridil, Carbamazepine, Chloroquine, Cisapride, Citalopram, Clarithromycin, Clozapine, Conivaptan, Darunavir, Dasatinib, Degarelix, Delavirdine, Digoxin, Dihydroergotamine, Disopyramide, Dolasetron, Efavirenz, Ergotamine, Grapefruit Juice, Halofantrine, Haloperidol, Indinavir, Itraconazole, Ketoconazole, Lapatinib, Levofloxacin, Lopinavir, Methadone, Midazolam, Moxifloxacin, Oxcarbazepine, Pazopanib, Phenobarbital, Phenytoin, Pimozide, Procainamide, Quinidine, Rifampin, Rifapentine, Ritonavir, Sotalol, St John's Wort, Telavancin, Telithromycin, Terfenadine, Voriconazole, Vorinostat, Ziprasidone
- See adverse reactions attributed to class:
Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor)
Vascular endothelial growth factor (VEGF) inhibitor / antagonist
Contra-indicated in patients with hypokalemia, hypomagnesemia, or long QT syndrome.
QT PROLONGATION AND SUDDEN DEATHS
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of nilotinib in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 08/07/2024
